A randomized, double-blind, placebo-controlled, human clinical trial just published in the Journal of the International Society of Sports Nutrition showed that those who consumed 2.4 grams of Kyowa’s L-citrulline significantly increased plasma L-arginine levels and a reduction in time to complete a cycle ergometer exercise trial.* With increasing consumer interest in sports nutrition, this study is a welcome addition to a growing body of research on Kyowa’s L-citrulline’s ability to support sports performance benefits.*

READ THE STUDY HERE

For more information visit: Kyowa Hakko USA

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Gnosis is delighted to announce that on February 22nd, 2016 the Brazilian National Health Surveillance Agency, ANVISA, has approved the use of vitaMK7^®, the Natural Vitamin K2 as MK7, as Novel Food Ingredient to be used in finished products in Brazil.

Vitamin K2 has been added to the Official Diary of the Union (Diário Oficial da União Brazil’s, DOU, equivalent to the U.S. Federal Register) and allows the commercialization of both vitaMK7® powder and oil grades.

Brazil is the only country in Latin America to have a well-defined legislation for functional and health claims for either nutrient or non-nutrient components.

ANVISA has positively approved vitaMK7^®, after a deeply evaluation of safety in accordance to current ANVISA regulations.

VitaMK7^® is the active isomer of natural Vitamin K2 with the highest bioavailability and longest half-life in the blood, exclusively manufactured by Gnosis through a fermentation process of Bacillus subtilis spp natto

In the latest Energy special we have collected ingredients to energize your formulations.

• Newcaff
• Fiit-NS
• Sabeet
• Cococin
• Saberry
• Watts’UP
• TeaCrine

You can read the newsletter HERE.

More innovative ingredients can be found in the Energy category.

Another Independent Clinical Trial Confirms NEM® Brand Eggshell Membrane’s Rapid Pain Reduction

Carthage, MO USA – Stratum Nutrition and joint-venture partner, ESM Technologies, the manufacturer of innovative, commercialized eggshell and eggshell membrane wellness ingredients, are pleased to announce a new independent clinical trial has published in the International Journal of Clinical Medicine evaluating their joint health ingredient NEM® brand eggshell membrane.

An independent, clinical trial conducted in Italy by Phytonature sas (Bovolone, Italy) confirmed the rapid reduction in pain found with NEM® brand eggshell membrane as in prior clinical trials. The study recruited 25 subjects with moderate, persistent knee osteoarthritis. The study participants were supplemented once daily with a capsule containing 500 mg of NEM® for 30 days and were evaluated at 10 & 30 days using a short-form questionnaire based upon the WOMAC questionnaire. The researchers found statistically significant reductions in pain as early as 10 days, with nearly three-quarters of the participants feeling at least a 40% improvement in this short time. The improvement continued throughout the end of the study (- 66.4%). Importantly, rescue analgesic use dropped 78% in the first 10 days of the study, and all 25 subjects consumed no analgesic through the remaining 20 days of the study. There were no serious adverse events in the study, and NEM® was reported to be well tolerated. The researchers concluded that this trial validates the clinical results seen with NEM® previously and that NEM® provides a viable natural treatment option for osteoarthritis of the knee. The results of the peer-reviewed study were recently published online in the International Journal of Clinical Medicine (http://dx.doi.org/10.4236/ijcm.2016.72017).

“We’re always pleased when an independent study is conducted that corroborates our own clinical results, particularly when it confirms NEM’s fast onset of efficacy. And this is the second such independent trial conducted in Europe. The Italian researchers did an excellent job of demonstrating that NEM® can have a very real impact on one’s quality of life through a reduction in the need to take analgesics on a daily basis.” commented Kevin J. Ruff Ph.D., MBA, CCRP –Sr. Director of Scientific & Regulatory Affairs for Stratum Nutrition.

For more information on this new published data, please contact Dr. Kevin Ruff at Kevin.Ruff@StratumNutrition.com.

About Stratum Nutrition and ESM Technologies
Stratum Nutrition, a Novus International Business, is Empowering Product Innovation through functional and specialty ingredients for manufacturers and marketers of foods, beverages and supplementation. Stratum offers a portfolio of branded, value-added ingredients that are progressive, safe and reliable. These ingredients are based on consumer need, supported by science and the backing of a trusted multinational company. ESM Technologies is the manufacturer of eggshell calcium and eggshell membrane wellness ingredients: ESC® and NEM®. The company researches, develops and manufactures high-quality branded ingredients from a traceable and sustainable supply of eggshells from USDA-inspected facilities. More information about Stratum Nutrition HERE.

Rimouski (Quebec) – innoVactiv, a Canadian company dedicated to the development of science-based specialty ingredients, announces new study results demonstrating for the first time the superior potency of InSea2^® the upcoming Engredea tradeshow (Booth # 764; March 11-13, Anaheim, CA).

InSea2^® is a non-GMO, organic-certified brown seaweed extract that is well-established for its best-in-class ability to optimize post-meal carbohydrate absorption and assimilation. Since it contains mostly phlorotannins, a polyphenol found exclusively in brown seaweeds, InSea2^® was always expected to show antioxidant benefits. “Free radicals are a driving force behind aging processes and their production is stimulated when blood glucose and insulin levels are high, such as after a meal. Our new study found that not only InSea2^® are also among the most potent antioxidants available to the dietary supplement industry, outperforming well-known antioxidants such as green tea, blueberry, cranberry and grape seed extracts.” said Jocelyn Bérubé, Executive and Scientific Director at innoVactiv.

“These results come as the area of seaweed research is boiling up with exciting new studies. Earlier this month, a new research from Corona et al. published in the British Journal of Nutrition showed for the first time how phlorotannins from brown seaweeds are digested, absorbed and metabolized. The research team also found that a single 100 mg dose of seaweed phlorotannins was sufficient to induce anti-inflammatory effects.” continued Mr. Bérubé.

“We are thrilled by what our findings and those from academia are suggesting. This means that can reduce oxidative stress not only through its clinically-demonstrated optimizing action on InSea2^® blood sugar, but also by acting itself as a source of high potency antioxidants with demonstrated bioavailability. This offers an extended range of health applications for InSea2^® optimization such as heart and circulatory health, eye health, skin health and much more.”, said Patrice Dionne, CEO of innoVactiv.

About innoVactiv
innoVactiv’s mission is to develop and supply innovative health ingredients with scientific demonstrations of efficacy and safety for the nutraceutical and cosmeceutical industries. www.innovactiv.com.

Source
innoVactiv inc.
Patrice Dionne
Chief Executive Officer
pdionne@innovactiv.com
418-721-2308 ext. 222

Dunedin, New Zealand and Saint Charles, MO USA – Blis Technologies and Stratum Nutrition are pleased to announce a new publication in the journal, Therapeutics and Clinical Risk Management, of an independent clinical trial evaluating the oral probiotic, BLIS K12®, and its effectiveness in preventing pharyngo-tonsillar infections, or recurrent tonsillitis, in children. The study was conducted using BLIS K12, a rare strain of Streptococcus salivarius. (DOI: http://dx.doi.org/10.2147/TCRM.S96134)

For this single-center, interventional-observational, independent study, 130 children with a history of GABHS (group A beta-hemolytic streptococci) infections were evaluated – 76 of which were enrolled in a 90-day program requiring a once-a-day dose of a lozenge with BLIS K12 the remaining 54 children served as the control group receiving no probiotic. Each subject was monitored for the occurrence of GABHS pharyngo-tonsillitis for at least 12 months following their entry into the study.

Results showed that 88% of the treatment group experienced no pharyngo-tonsillar infections compared to only 22% of the untreated group. Even 9 months after the use of BLIS K12 had been stopped, the development of new pharyngo-tonsillitis infections was significantly lower when compared to the period before treatment. The results from this study are supportive of previous studies conducted on BLIS K12, where prophylactic administration of BLIS K12 to children with a history of recurrent oral streptococcal infection resulted in clinically meaningful reductions in the episodes of both streptococcal and viral infections, along with concomitant reductions in the number of days using an antibiotic and days absent from school.

Dr. Joseph Evans, Executive Manager of Research & Development for Stratum Nutrition, Blis Technologies’ North American distributor, commented, “Streptococcus salivarius BLIS K12 has once again demonstrated its clinically meaningful efficacy and unchallenged safety profile in a population whose only other current option for supporting their throat health is an antibiotic. As we enter the era of personalized nutrition, the stage is set for Streptococcus salivarius BLIS K12 to benefit those children and adults who desire a natural approach to optmize their oral and throat health.”

Blis Technologies chief executive Brian Watson said this trial adds to the steadily building body of evidence coming in from around the world backing the efficacy of Streptococcus salivarius BLIS K12. “There is clearly a deep shift in thinking about how personal and population health is managed, particularly around the microbiome, and that shift is impacting demand for these products.”

Citation: Gregori G, et al. (2016) Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study. Ther Clin Risk Manag. 12:87-92. http://dx.doi.org/10.2147/TCRM.S96134

About Blis Technologies
Blis Technologies is the manufacturer of oral probiotic products based on the natural human mouth bacterium Streptococcus salivarius. Stratum Nutrition is the exclusive North American distributor of BLIS probiotic products including BLIS K12 and BLIS M18. BLIS K12® is a probiotic member of the bacterial species Streptococcus salivarius developed in Dunedin, New Zealand for the support of oral health. Visit: Stratum Nutrition

Twenty-Five Year Veteran of Food and Consumer Products Quality Management Operations Will Drive Company’s PLT360™ Initiative

Morristown, NJ – PLT Health Solutions, Inc. announced the appointment of Craig Stapleton as the company’s Director of Quality Assurance. Mr. Stapleton brings a background in food science and over twenty-five years in food and consumer quality management to PLT, including over a decade in a broad range of quality functions at Unilever/Bestfoods and similar postings at natural foods and consumer products companies. In his new position he will lead the implementation and ongoing management of quality programs, policies and strategies that respond to client and industry standards. Stapleton will also be a driver of PLT’s recently announced PLT360 initiative. PLT360 is a business-wide commitment by PLT Health Solutions to drive customer confidence in ingredients that are safe, of high quality, efficacious and harvested and manufactured in a sustainable way. Going beyond traditional quality control programs, PLT360 examines every aspect of an ingredient to deliver best-in-class solutions. As part of its commitment to participating in an industry-wide dialogue on transparency and quality, PLT Health Solutions will be a major sponsor at the UNPA Raw Materials & Supply Chain Summit in Salt Lake City this month.

According to Barbara Davis, Vice President, Medical & Scientific Affairs at PLT Health Solutions, the appointment of Stapleton is a part of the company’s drive to incorporate best industry practices in every phase of its business, managed by experienced, top quality personnel. “We work with some of the best companies in the world enabling them to develop consumer products and strong brands to support healthy lifestyles. Quality and trust-building are more important than they have ever been in the health and wellness space. At PLT, we continue to focus our efforts in building state-of-the-industry quality systems and to communicating the impact and benefits of these systems to our customers,” she said. “Craig Stapleton has a track record of leadership, creativity and success in quality management for food and consumer products – so he understands the needs of our customers. We’re excited to have him as a senior member of the PLT team and look forward to introducing him to our customers,” she added.

PLT360 – A new value creation approach for natural ingredients
In late 2015, PLT announced a formal transparency and trust-building initiative for its ingredient portfolio – called PLT360. The initiative is designed to support emerging opportunities for food, beverage and supplements companies that can deliver assured ingredient quality, demonstrable efficacy, and clean labels in consumer products. Going beyond traditional quality control programs, PLT360 examines every aspect of an ingredient, tracking Ingredient Integrity, Quality, Sustainability and Efficacy.

Prior to joining PLT, Mr. Stapleton was Global Quality Assurance Manager – Hygiene for Reckitt Benckiser’s Lysol and Dettol Brands. Over a 10-year career at Reckitt Benckiser, he served in similar capacities in Personal Care and Food – including French’s Foods North America. Earlier in his career, Mr. Stapleton worked for more than a decade in a broad range of quality management functions across diverse product types at Unilever/Bestfoods
Mr. Stapleton graduated with a BS in Food Science from Montclair State University and was awarded an MBA in Industrial Management from Farleigh Dickinson University. He is a Certified HACCP and SQF Practitioner and is ASQ Six Sigma Black Belt (SQBB) certified. He is a member of the Institute for Food Technologists (IFT), American Society for Quality (ASQ) and the Institute of Supply Management (ISM).

About PLT Health Solutions
Headquartered in Morristown, NJ, USA, PLT Health Solutions is a trusted discoverer, developer, and marketer of high-quality, scientifically-supported ingredients that enhance health and functionality. As a leading ingredients innovator, PLT’s global network of strategic partnerships provides unique access to impactful solutions. By delivering an unsurpassed mix of expertise, resources, and service, PLT is committed to helping both its strategic partners and valued customers grow.

More information about PLT Health Solutions HERE.

After Receiving ‘Letter of No Objection’ from US FDA.

Dunedin, New Zealand and Saint Charles, MO USA – Blis Technologies and Stratum Nutrition are pleased to announce that a ‘Letter of No Objection’ has been received from the US Food and Drug Administration (FDA) for one of the company’s key products, oral probiotic BLIS K12^®. A ‘Letter of No Objection’ refers to the letter sent by the FDA confirming that they do not question the basis for the GRAS self-affirmation notification submitted by Blis Technologies.

Blis Technologies board chairman Peter Fennessy said the Letter of No Objection is another step on the strategic pathway to opening markets through regulatory approval.

“It adds a new level of credibility for BLIS K12 and puts the conversations with larger consumer food and beverage companies in the US on a stronger footing.”

“Many of those companies are, quite rightly, risk averse. Therefore, having the non-objection notification from the FDA offers an additional level of confidence and makes it clearer where BLIS K12 fits within the category.”

Through the GRAS notification program, companies voluntarily submit their self-affirmation dossier, substantiated by extensive research and expert peer review, that a specific ingredient is Generally Recognized As Safe. The ‘Letter of No Objection’ means that FDA has reviewed all of the scientific data on BLIS K12 and has no questions or concerns regarding its safety.

BLIS K12 is an oral cavity probiotic that has been shown in multiple published clinical trials to provide benefits for supporting ear and throat health in both children and adults.

Jeremy Moore, Managing Director of Blis Technologies’ North American distributor, Stratum Nutrition, says, “Very few ingredients in this space go to this level, so it is a definite feather in the cap for Blis.”

Blis Technologies
Blis Technologies is the manufacturer of oral probiotic products based on the natural human mouth bacterium Streptococcus salivarius.

Stratum Nutrition
Stratum Nutrition is the exclusive North American distributor of BLIS probiotic products including BLIS K12® and BLIS M18™.

BLIS K12
BLIS K12 is a probiotic member of the bacterial species Streptococcus salivarius developed in Dunedin, New Zealand for the support of oral health.

Visit http://www.stratumnutrition.com/ingredients/blis-k12/ for more information on BLIS K12.

Judges to select one company’s product concept for a partnership to make probiotic history

CLEVELAND, OH – In an effort to cultivate probiotic innovation in the functional food and beverage market, Ganeden^® has announced Probiotic Innovation Jumpstart — an industry-first entrepreneurial program designed to help companies launch new probiotic products.

The program from Ganeden is an opportunity that invites all scientists, entrepreneurs and inventors with a brand-new probiotic food or beverage product concept to submit their idea to Ganeden. While entries will be accepted for all product categories, the company encourages submissions for novel products that will resonate with consumers and fill a specific need in the marketplace. The grand-prize winner will receive $25,000 in support to utilize GanedenBC30^® probiotics in the product, as well as the guidance, assistance and expertise needed to help develop and launch their innovation into the food and beverage industry.

“Ganeden’s growth and success has been accomplished by helping hundreds of forward-thinking companies around the world develop and market innovative, first-of-their-kind probiotic products,” said Andy Lefkowitz, Ganeden’s CEO. “The future of the food and beverage market is functional foods, and we see this program as a huge opportunity to share our expertise and support the industry by helping others bring their ideas to life and onto shelves.”

All initial concepts must be submitted on the Probiotic Innovation Jumpstart website by May 6, 2016. Three finalists will then be chosen to present their ideas in-person to a panel of esteemed judges during the Institute of Food Technologists (IFT) show in Chicago on July 16, 2016. The presentations, to be done by two representatives from each company, will be judged by a panel of respected industry experts from both manufacturing and retail backgrounds. The panel includes Mark Retzloff, a pioneer in the organic and natural foods industry, and Caroline Beckman, co-founder and CEO at Nomva.

“This is a wonderful opportunity to help nurture our fantastic industry, and I am humbled to be a judge for Ganeden’s program,” said Mark Retzloff, senior partner for the Boulder Farm Team and chairman for multiple food & beverage boards. “I’ve personally watched products containing GanedenBC30 gain significant traction in the marketplace, and look forward to seeing the success that this program will bring.”

To learn more about Ganeden’s Probiotic Innovation Jumpstart program or to submit a product idea, visit Ganedenprobiotics.com/jumpstart. For information on GanedenBC30 probiotics, visit Ganedenbc30.com.

About Ganeden
Ganeden is at the forefront of probiotic research and product development with an extensive library of published studies and more than 100 patents for probiotic technologies in the food, beverage, animal health, sports nutrition and personal care ingredients markets. Ganeden is best known for GanedenBC30® (Bacillus coagulans GBI-30, 6086), its patented, FDA GRAS, non-GMO, highly stable probiotic ingredient. Ganeden’s newest ingredient, Bonicel, is the first science-backed, probiotic-derived, personal care ingredient shown to dramatically reduce signs of aging. For more information about Ganeden and licensing opportunities visit GanedenProbiotics.com.

About GanedenBC30^®
GanedenBC30^® (Bacillus coagulans GBI-30, 6086), Ganeden’s patented probiotic ingredient that can be found in more than 150 leading food, beverage, sports nutrition and companion animal products around the world. Unlike most other probiotic strains, GanedenBC30 is a spore-former which makes it highly stable and allows it to remain viable through most manufacturing processes, three years of shelf life and the low pH of stomach acid. The efficacy of GanedenBC30 is backed by over 20 published studies showing safety, digestive and immune support and GanedenBC30 has an exceptional safety record with FDA GRAS status from the United States FDA. It can be formulated into virtually any food, beverage or companion animal product that is baked, boiled, frozen or squeezed… including all hot or refrigerated beverages! For more information, please visit GanedenBC30.com.

DESIO, Italy – Newly results about association between prenatal folate status and children’s brain anatomy have been showed in a research published in the British Journal of Nutrition in early 2016 (Ars et al 2016 – Prenatal folate, homocysteine and vitamin B12 levels and child brain volumes, cognitive development and psychological functioning.) The research suggests that prenatal maternal folate deficiency in early pregnancy has a long-lasting global effect on brain development in offspring and has been associated with smaller total brain volume, poorer language and visuo-spatial performance in children aged between 6 and 8 years.

Quatrefolic^®, as a source of the active form of folate, the (6S)-5-methyltetrahydrofolate (5-MTHF), can be the first choice in the folate supplementation. Quatrefolic^® maximizes the benefit of folate supplementation without incurring in fruitless effect of other sources of folate, protecting mothers in pregnancy and, according to the study above, young children. Read more about this study and join our network to stay always up-to-date on the latest news about the world of folates!

Read more about this study and join our network to stay always up-to-date on the latest news about the world of folates!